Biotechnology company developing chimeric antigen receptor macrophage (CAR-M) therapies for solid tumors.
Carisma Therapeutics, Inc. operates as a dynamic clinical-stage cell therapy company at the forefront of developing cutting-edge immunotherapies aimed at treating cancer and other severe illnesses across the United States. Founded in 2016 and headquartered in Philadelphia, Pennsylvania, the company focuses on pioneering ex vivo CAR-M cell therapies that harness the power of modified immune cells for therapeutic purposes.
Among its innovative pipeline, Carisma Therapeutics features several promising candidates. CT-0508, a CAR-macrophage, is currently undergoing Phase 1 clinical trials targeting solid tumors. Similarly, CT-0525, a CAR-monocyte, is also in Phase 1 trials for treating solid tumors. Additionally, the company is advancing CT-1119, a mesothelin-targeted CAR-Monocyte, through pre-clinical stages to address advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, and ovarian cancer.
In collaboration with Moderna Therapeutics, Carisma Therapeutics is exploring in vivo CAR-M cell therapies tailored to combat multiple cancer targets. Beyond oncology, the company is actively developing a diverse portfolio of assets with potential applications in treating diseases such as fibrosis, as well as various immunologic and inflammatory conditions.
Formerly known as CARMA Therapeutics Inc., the company rebranded as Carisma Therapeutics, Inc. in May 2017, signaling its evolution and expanded focus within the biotechnology landscape. With a dedication to advancing transformative therapies and improving patient outcomes, Carisma Therapeutics continues to push the boundaries of cell therapy innovation, leveraging its strategic location in Philadelphia to drive progress in the field of immunotherapy.